breast cancer
Breast Cancer's Financial Toll, Part 2: Where to Go for Help
8:00AM 10/06/2011
A breast cancer diagnosis can be like an earthquake in the life of the patient and her family, but the medical community is there to help guide them. What's often hard to find is a monetary lifeline for those in danger of getting washed away by the financial tidal wave that can follow.
Breast Cancer's Financial Toll: The High Cost of Fighting for Your Life
11:00AM 10/05/2011
Breast cancer is the second most common cancer among American women: 12% will develop it at some point in their lives, and at that point, the health battle begins. But those women often must fight one a second front as well, dealing with the multiple threats cancer poses to their financial well-being.
The Susan G. Komen Foundation's partnerships bring in millions each year for breast cancer research. But one of its partners has brought it an ironic problem: The perfume Promise Me, marketed to benefit the charity, contains a hormone disruptor that studies point to as a contributing cause of breast cancer.
Another Cancer-Drug Failure Highlights Difficulties Facing Pharmas
12:30PM 1/28/2011
Company News, Columns, Health Care, Genzyme Corporation , Pfizer, Bristol-Myers Squibb, Sanofi Aventis, Novartis, Eli Lilly, Astrazeneca
Sanofi-Aventis announced its cancer drug candidate iniparib failed in a late-stage clinical trial. Other pharmaceutical companies have also experienced recent setbacks as they scramble to bolster their pipelines ahead of the patent cliff, when they will be forced to compete with cheaper generics.
Wyeth Loses Appeal Over Hormone Replacement Drugs
9:00PM 11/24/2010
Wyeth Pharmecuticals on Wednesday lost its appeal of a decision that awarded $58 million in damages to three women who claimed the company's hormone-replacement drugs caused their breast cancer. The news could bode badly for the Pfizer-owned company, which has thousands of such cases pending.
Cure for cancer stalls, but pink puts companies in the black
2:00PM 10/27/2010
The idea of associating pink with the battle against breast cancer has unquestionably worked as a marketing tool. But how do you sort legitimate support for the cause from shameless product marketing when both use the same symbol?
Experts say even the most questionable campaigns help heighten...
FDA Setback for Roche and Immunogen Breast Cancer Treatment
9:45AM 8/27/2010
The FDA denied accelerated approval of Roche's trastuzumab-DM1 (T-DM1) license application. T-DM1 is a potential breast cancer treatment. Roche will continue with its trials and plans a global regulatory submission in mid-2012.
FDA Panel Recommends Rejecting Avastin for Breast Cancer
3:00AM 7/21/2010
Roche's blockbuster cancer drug, Avastin, could lose its U.S. Food and Drug Administration approval for use against breast cancer after an FDA panel recommended the withdrawal. Studies failed to show the drug extends breast-cancer patients' lives, panelists say.
A study published Tuesday suggests that use of cleaning products contributes to increased breast cancer risk. If you were hoping this study could give you reasons to clean less, even the study authors note the evidence is far from conclusive.
Most insurers to limit policy cancellations by May
11:00AM 4/30/2010
We probably won't be seeing many more stories of people losing their health insurance when diagnosed with cancer or for any other reason except fraud. That practice will end by May for many insurers who practice it. The new health care law mandates that rescission (cancellation of an insurance...
More Stories
Next Page →Market Movers
| Symbol | Last | Change / % | Volume |
|---|
Most Actives
| 8.07 | -0.11 -1.34% | 254.23M | |
| 2.19 | +0.25 +12.89% | 122.18M | |
| 18.88 | -0.26 -1.33% | 109.55M | |
| 12.44 | -0.25 -1.97% | 52.49M |
% Gainers
| 31.68 | +7.78 +32.55% | 18.42M | |
| 89.96 | +13.57 +17.76% | 13.27M | |
| 2.19 | +0.25 +12.89% | 122.18M | |
| 10.50 | +1.10 +11.70% | 3.07M |
% Losers
DailyFinance Wire
- 4 Money-Etiquette Questions Answered
- Walmart's New Health Food Push: Is It Too Hard to Swallow?
- Newlyweds, Don't Let the IRS Spoil Your Honeymoon
- Bonds Are a 'Safe' Investment: A Big Lie Gets Even Bigger
- Why Groupon Will Never Be Great Again
- Why Used Car Bargains Are Getting Harder to Find
- 5 Reasons Facebook Stock May Be a Better Buy Than You Think
Newswire
- Greece's grim choice: deep budget cuts or...
- Greek premier defends bailout deal, painful...
- Faces beyond the numbers of long-term...
- Staff at The Sun tabloid arrested in bribe...
- Obama budget: New spending with recycled tax...
- Obama budget seeks to boost trade enforcement
- As Facebook IPO nears, the case for dull stocks
- Turbo-traders take Bank of America for a ride
- Getting paid $35,000 to short sell
- What the $26B settlement means for you
- Investing your emergency cash: Return vs. risk
- First Premier's $400-a-year credit card
- Big banks' bloated mortgage tab
- Fewer young adults hold jobs than ever before
- Government assistance expands
- Bob Rodriguez: The best advice I ever got
- 24/7 Wall St. Top Analyst Calls of the Week (AONE, ALU, AMSC, NLY, AAPL, CSCO, COH, CSTR, COP, DLR, IBM, LF, MMM, M, OPEN, POST, SIRI, SOHU, TRLG, ZOLT)
- The Force: Star Wars Franchise Worth Over $30 Billion and Growing
- 24/7 Wall St. Closing Bell (COP, GILD, AMSC, MA, COH, LNKD, ATVI, CPST, GPRE, KONA, TRLG, LGF, MOVE, NBL, PCYC, ALU, FLIR, RUTH, FSLR, CIE, TBAC, RPXC, AMRS)
- Mid-day Movers (CIE, AMRS, IPSU, MOVE, LNKD)
- Petrobras Shares Volatile on $225 Billion Development Plan (PBR)
- Morning Movers (CIE, ALU, LNKD, AMRS, XIDE)
- AEP Dividend Growth Still Looks Safe Ahead (AEP)
- Arch Coal Tumbles on Earnings, Forecast (ACI, ANR, PCX, BTU, CNX)
Follow Us
